The molecular genetics of RASopathies : An update on novel disease genes and new disorders
American Journal of Medical Genetics Part C: Seminars in Medical Genetics · 2022-12 · 190 (4) · 425-439
DOI: 10.1002/ajmg.c.32012 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift American Journal of Medical Genetics Part C: Seminars in Medical Genetics, online erschienen am 16.11.2022. Verfasst von Marco Tartaglia und 2 weiteren Autor:innen. Beteiligte Einrichtung: Genetics and Rare Diseases Research Division, Ospedale Pediatrico Bambino Gesù, IRCCS, Rome, Italy. Hauptthemen laut MEDLINE: Noonan Syndrome, ras Proteins, Signal Transduction. Die Arbeit wurde bisher 103-mal zitiert (Crossref) und nennt 129 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NHLBI NIH HHS, Associazione Italiana per la Ricerca sul Cancro, Japan Agency for Medical Research and Development.
Abstract (Originalsprache)
Enhanced signaling through RAS and the mitogen‐associated protein kinase (MAPK) cascade underlies the RASopathies, a family of clinically related disorders affecting development and growth. In RASopathies, increased RAS‐MAPK signaling can result from the upregulated activity of various RAS GTPases, enhanced function of proteins positively controlling RAS function or favoring the efficient transmission of RAS signaling to downstream transducers, functional upregulation of RAS effectors belonging to the MAPK cascade, or inefficient signaling switch‐off operated by feedback mechanisms acting at different levels. The massive effort in RASopathy gene discovery performed in the last 20 years has identified more than 20 genes implicated in these disorders. It has also facilitated the characterization of several molecular activating mechanisms that had remained unappreciated due to their minor impact in oncogenesis. Here, we provide an overview on the discoveries collected during the last 5 years that have delivered unexpected insights (e.g., Noonan syndrome as a recessive disease) and allowed to profile new RASopathies, novel disease genes and new molecular circuits contributing to the control of RAS‐MAPK signaling.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Genetics and Rare Diseases Research Division, Ospedale Pediatrico Bambino Gesù, IRCCS, Rome, Italy.
- Department of Medical Genetics, Tohoku University School of Medicine, Sendai, Japan.
- Mindich Child Health and Development Institute, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
- Department of Pediatrics and Genetics, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
- Department of Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
ORCID-Profile: Marco Tartaglia, Bruce D Gelb
Förderung
- NHLBI NIH HHS
- Associazione Italiana per la Ricerca sul Cancro
- Japan Agency for Medical Research and Development
- National Institutes of Health
Zitieren
APA
Tartaglia, M., Aoki, Y., & Gelb, B. D. (2022). The molecular genetics of RASopathies : An update on novel disease genes and new disorders. American Journal of Medical Genetics Part C: Seminars in Medical Genetics, 190(4), 425-439. https://doi.org/10.1002/ajmg.c.32012
Vancouver
Tartaglia M, Aoki Y, Gelb BD. The molecular genetics of RASopathies : An update on novel disease genes and new disorders. American Journal of Medical Genetics Part C: Seminars in Medical Genetics. 2022;190(4):425-439. doi:10.1002/ajmg.c.32012
BibTeX
@article{Tartaglia2022,
author = {Tartaglia, Marco and Aoki, Yoko and Gelb, Bruce D},
title = {The molecular genetics of RASopathies : An update on novel disease genes and new disorders},
journal = {American Journal of Medical Genetics Part C: Seminars in Medical Genetics},
year = {2022},
volume = {190},
number = {4},
pages = {425--439},
doi = {10.1002/ajmg.c.32012}
}
EUVIMED